Fed Cuts Rates by Quarter Point, Some ETFs up 12%, 70% on Year. Is it all in the Software?

On the heels of a quarter point cut in the federal funds discount rate, stocks closed lower today. Leading the declines were financial stocks, which had been rising on hopes of strong Fed action to resolve the credit-market crisis, and stocks of companies whose profits are most closely tied to economic growth, such as transportation firms, retailers and industrial companies.

Smaller stocks suffered more than big ones, on the theory that they are less stable in times of economic trouble. Technology stocks closed lower also. The Nasdaq Composite Index dropped 2.5% Tuesday.

However, an Exchange Traded Fund (ETF) that shorts real-estate values was up nearly 12% on the day, and an ETF based on the Brazilian economy is up 70% for the year. International markets and selective investment instruments that are betting on the devaluation of real estate have performed well this year. This compared to an ETF that is tied to an index in selected tech stocks, which is only up approximately 12% for the year.

ETFs, which trade on exchanges like a stock and generally track various stock and bond indexes, already had lower expenses on average than traditional mutual funds. So now investors can find razor-thin expense ratios for some ETFs that track broad-based indexes of market sectors like international stocks, U.S. growth stocks or municipal bonds. But investors’ infatuation with ETFs also has prompted several firms to introduce much pricier versions that seek higher returns by following offbeat and narrow indexes, such as ones tracking European drug companies or using computer-based algorithms to pick stocks. Such algorithms might be described visually, in their simple form as a flow chart using a lamp scenario to illustrate (see below):


Essentially, investors are paying for the quality of software, programmed with scenarios (or, as above, algorithms) and the added value of the managers who review the investments indicated by the algorithm that simulate market conditions.

No World Borders can help you assess the value of intellectual property (IP) that is in the form of software.

Here is a video from the WSJ with Chief Investment Officer Bob Doll of BlackRock with his reaction to the rate cut by the Fed today:

health care process improvement, electronic health record, electronic medical record, management consulting, human and investment capital, outsourcing. Specializing in health care, financial services, education, renewable energy, retail. www.noworldborders.com

Michael F. Arrigo

Michael is Managing Partner & CEO of No World Borders, a leading healthcare management and IT consulting firm. He serves as an expert witness in Federal and State Court and was recently ruled as an expert by a 9th Circuit Federal Judge. He serves as a patent expert witness on intellectual property disputes, both as a Technical Expert and a Damages expert. His vision for the firm is to continue acquisition of skills and technology that support the intersection of clinical data and administrative health data where the eligibility for medically necessary care is determined. He leads a team that provides litigation consulting as well as advisory regarding medical coding, medical billing, medical bill review and HIPAA Privacy and Security best practices for healthcare clients, Meaningful Use of Electronic Health Records. He advises legal teams as an expert witness in HIPAA Privacy and Security, medical coding and billing and usual and customary cost of care, the Affordable Care Act and benefits enrollment, white collar crime, False Claims Act, Anti-Kickback, Stark Law, physician compensation, Insurance bad faith, payor-provider disputes, ERISA plan-third-party administrator disputes, third-party liability, and the Medicare Secondary Payer Act (MSPA) MMSEA Section 111 reporting. He uses these skills in disputes regarding the valuation of pharmaceuticals and drug costs and in the review and audit of pain management and opioid prescribers under state Standards and the Controlled Substances Act. He consults to venture capital and private equity firms on mHealth, Cloud Computing in Healthcare, and Software as a Service. He advises ERISA self-insured employers on cost of care and regulations. Arrigo was recently retained by the U.S. Department of Justice (DOJ) regarding a significant false claims act investigation. He has provided opinions on over $1 billion in health care claims and due diligence on over $8 billion in healthcare mergers and acquisitions. Education: UC Irvine - Economics and Computer Science, University of Southern California - Business, studies at Stanford Medical School - Biomedical Informatics, studies at Harvard Medical School - Bioethics. Trained in over 10 medical specialties in medical billing and coding. Trained by U.S. Patent and Trademark Office (USPTO) and PTAB Judges on patent statutes, rules and case law (as a non-attorney to better advise clients on Technical and Damages aspects of patent construction and claims). Mr. Arrigo has been interviewed quoted in the Wall Street Journal, New York Times, and National Public Radio, Fortune, KNX 1070 Radio, Kaiser Health News, NBC Television News, The Capitol Forum and other media outlets. See https://www.noworldborders.com/news/ and https://www.noworldborders.com/clients/ for more about the company.